Fatty Liver Disease Clinical Trial
Official title:
Effects of Tablets of Silybum Marianum, Pueraria Lobate and Salvia Miltiorrhiza on the Progression of Fatty Liver in Adults: a Double-blinded Randomized Placebo-controlled Clinical Trial
Objectives: To examine the effects of tablets of silybum marianum, Pueraria lobate and salvia miltiorrhiza on the progression of fatty liver in patients with fatty liver. Design: a double-blinded randomized placebo-controlled clinical trial. Setting: community residents, Guangzhou city, South China. Participants: a total 118 men and women (18-65 years), with BMI range of 24-30 kg/m2, and with fatty liver screened by ultrasound or MR at baseline. Arms and Interventions: 118 participants were randomly allocated into two arms using a block randomization method. Experimental Arm: tablet of silybum marianum, Pueraria lobate and salvia miltiorrhiza, 3 tablets (1g each) twice a day for 6 months; Placebo Arm: placebo tablets, 3 tablets (1g each) twice a day for 6 months. Outcome Measures: determined at baseline and at 6 months post treatment 1. Primary Outcome Measures: 1) proton density fat fraction of liver assessed by MR; 2) serum liver fibrosis biomarkers: type procollagen III N terminal peptide, hyaluronic acid, laminin, collagen type IV, and glycocholic acid; 3) NAFLD fibrosis score. 2. Secondary Outcome Measures: 1) serum liver function biomarkers: AST, ALT, GGT, ALP, total protein, and bile acids; 2) fasting blood lipids: total triglycerides, total cholesterol, HDL cholesterol and LDL cholesterol; 3) fasting serum glucose and insulin; 4) serum inflammatory factors (hsCRP and IL-6); 5) oxidative stress: SOD and MDA; and 6) body measurements and body fat mass. Data Analyses: Mean changes in the above outcome measures from baseline to 6 months will be compared between the two arms.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05881005 -
NAC- NAFLD And Cushing
|
N/A | |
Recruiting |
NCT05220956 -
Impact of Time-restricted Feeding in NAFLD
|
N/A | |
Enrolling by invitation |
NCT04066608 -
Prevalence of Advanced Fibrosis in Patients Living With HIV
|
||
Recruiting |
NCT04302051 -
Assessment of Fatty Liver With Thermo-acoustic Device
|
||
Recruiting |
NCT04496895 -
The Evaluation of Orange Peel Fermentation on Body Fat Lowering Efficacy in Adults
|
N/A | |
Recruiting |
NCT05880316 -
Prevalence of MAFLD Among Nurses and the Role of Intermittent Fasting
|
N/A | |
Active, not recruiting |
NCT05898841 -
Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
|
Phase 4 | |
Completed |
NCT05764811 -
SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity
|
N/A | |
Recruiting |
NCT05421572 -
Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
|
||
Recruiting |
NCT06302049 -
Clinical Study Evaluating the Safety and Efficacy of Esomeprazole in Treatment of Non-alcoholic Steatohepatitis
|
Phase 1/Phase 2 | |
Completed |
NCT04283942 -
Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose Metabolism
|
N/A | |
Completed |
NCT01016418 -
Bovine Colostrum for Patients With Non Alcoholic Fatty Liver Disease
|
Phase 1/Phase 2 | |
Terminated |
NCT04175392 -
Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04191044 -
Portal Hypertension in Non-alcoholic Fatty Liver Disease: Association With Cardiovascular Risk and Identification of Non-invasive Biomarkers (THESIS)
|
||
Not yet recruiting |
NCT06071923 -
Effect of Thyroid Disorders in Liver Diseases
|
||
Recruiting |
NCT04525833 -
Liver Disease and Other Systemic Diseases
|
||
Not yet recruiting |
NCT05966025 -
Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)
|
Phase 2 | |
Completed |
NCT04844450 -
A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795
|
Phase 1 | |
Completed |
NCT04367012 -
Fatty Liver Among Employees at Banha University
|
||
Completed |
NCT05694923 -
Effect of Sodium Glucose Cotransporter Inhibitors on Non Diabetic Fatty Liver Disease Patients
|
N/A |